Abstract
Daytime symptoms resulting from obstructive sleep apnea (OSA) include impaired neurobehavioural performance and increased sleepiness. Continuous positive airway pressure (CPAP) reduces these symptoms. However, even compliant users may temporarily withdraw from CPAP treatment resulting in an immediate return of OSA. It has been hypothesised that these treatment “holidays” may be associated with neurobehavioural decline. Acute administration of a wakefulness promoter during such treatment “holidays” may help maintain neurobehavioural functioning. We examined the effects of 200 mg modafinil on neurobehavioural performance in a placebo-controlled crossover trial including N = 12 OSA patients acutely removed from CPAP. Sleep–wake activity was assessed for four consecutive days on CPAP and one night off CPAP using actigraphy. During the night off, CPAP patients wore a single channel nasal airflow diagnostic device. On the morning after CPAP withdrawal, patients reported to the laboratory and were administered either modafinil (200 mg) or placebo. At 2 h post-administration, patients completed a single simulated drive of approximately 30 min with simultaneous administration of a divided attention task (STISIM™), critical flicker fusion (CFF) test and subjective sleepiness scales. After a 14-day washout, participants repeated the protocol. CPAP withdrawal was associated with a worsening of sleep efficiency and the movement and fragmentation index (MFI), compared to the on-CPAP nights (all p ≤ 0.02). Modafinil did not result in a superior driving simulator performance or CFF responses the morning after CPAP withdrawal but did result in better subjective sleepiness (both p ≤ 0.04) compared to placebo. These data do not support the use of modafinil for the maintenance of daytime functioning in patients with OSA who are acutely withdrawn from CPAP.
Similar content being viewed by others
References
Peppard PE, Szklo-Coxe M, Hla KM, Young T (2006) Longitudinal association of sleep-related breathing disorder and depression. Arch Intern Med 166:1709–1715
Young T, Peppard PE, Gottlieb DJ (2002) Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165:1217–1239
Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ (2006) Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 3:CD001106
Boudewyns A, Sforza E, Zamagni M, Krieger J (1996) Respiratory effort during sleep apneas after interruption of long-term CPAP treatment in patients with obstructive sleep apnea. Chest 110:120–127
Fiz JA, Abad J, Ruiz J, Riera M, Izquierdo J, Morera J (1998) nCPAP treatment interruption in OSA patients. Respir Med 92:28–31
Grunstein RR, Stewart DA, Lloyd H, Akinci M, Cheng N, Sullivan CE (1996) Acute withdrawal of nasal CPAP in obstructive sleep apnea does not cause a rise in stress hormones. Sleep 19:774–782
Noseda A, Kempenaers C, Kerkhofs M, Houben JJ, Linkowski P (1996) Sleep apnea after 1 year domiciliary nasal-continuous positive airway pressure and attempted weight reduction. Potential for weaning from continuous positive airway pressure. Chest 109:138–143
Yang Q, Phillips CL, Melehan KL, Rogers NL, Seale JP, Grunstein RR (2006) Effects of short-term CPAP withdrawal on neurobehavioral performance in patients with obstructive sleep apnea. Sleep 29:545–552
Kribbs NB, Pack AI, Kline LR, Getsy JE, Schuett JS, Henry JN, Maislin G, Dinges DF (1993) Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea. Am Rev Respir Dis 147:1162–1168
Sforza E, Lugaresi E (1995) Daytime sleepiness and nasal continuous positive airway pressure therapy in obstructive sleep apnea syndrome patients: effects of chronic treatment and 1-night therapy withdrawal. Sleep 18:195–201
Bonnet MH, Balkin TJ, Dinges DF, Roehrs T, Rogers NL, Wesensten NJ (2005) The use of stimulants to modify performance during sleep loss: a review by the Sleep Deprivation and Stimulant Task Force of the American Academy of Sleep Medicine. Sleep 28:1163–1187
Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545
Buysse DJ, Reynolds CF (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213
Schwartz JE, Jandorf L, Krupp LB (1993) The measurement of fatigue: a new instrument. J Psychosom Res 37:753–762
Wong KK, Jankelson D, Reid A, Unger G, Dungan G, Hedner J, Grunstein R (2008) Diagnostic test evaluation of a nasal flow monitor for obstructive sleep apnea detection in sleep apnea research. Behav Res Meth Instrum Comput 40:360–366
Akerstedt T, Hume K, Minors D, Waterhouse J (1994) The subjective meaning of good sleep, an intraindividual approach using the Karolinska Sleep Diary. Percept Mot Skills 79:287–296
Leung S, Starmer G (2005) Gap acceptance and risk-taking by young and mature drivers, both sober and alcohol-intoxicated, in a simulated driving task. Accident Anal Prev 37:1056–1065
Curran S (1990) Critical flicker fusion techniques in psychopharmacology. Hum Psychopharmacol. Wiley, Chichester
Gillberg M, Kecklund G, Akerstedt T (1994) Relations between performance and subjective ratings of sleepiness during a night awake. Sleep 17:236–241
Hoddes E, Dement WC, Zarcone V (1972) The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiology 9:150
Kazis LE, Anderson JJ, Meenan RF (1989) Effect sizes for interpreting changes in health status. Med Care 27:S178–S189
Risser MR, Ware JC, Freeman FG (2000) Driving simulation with EEG monitoring in normal and obstructive sleep apnea patients. Sleep 23:393–398
George CF (2003) Driving simulators in clinical practice. Sleep Med Rev 7:311–320
Black JE, Hirshkowitz M (2005) Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 28:464–471
Dinges DF, Weaver TE (2003) Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 4:393–402
Pack AI, Black JE, Schwartz JR, Matheson JK (2001) Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 164:1675–1681
Li YF, Zhan H, Xin YM, Tang GX, Wei SH, Li T (2003) [Effects of modafinil on visual and auditory reaction abilities and subjective fatigue level during 48 h sleep deprivation]. Space Medicine & Medical Engineering (Beijing) 16:277–280
Hack M, Davies RJ, Mullins R, Choi SJ, Ramdassingh-Dow S, Jenkinson C, Stradling JR (2000) Randomised prospective parallel trial of therapeutic versus subtherapeutic nasal continuous positive airway pressure on simulated steering performance in patients with obstructive sleep apnoea. Thorax 55:224–231
Baulk SD, Reyner LA, Horne JA (2001) Driver sleepiness—evaluation of reaction time measurement as a secondary task. Sleep 24:695–698
Ayalon L, Ancoli-Israel S, Klemfuss Z, Shalauta MD, Drummond SP (2006) Increased brain activation during verbal learning in obstructive sleep apnea. Neuroimage 31:1817–1825
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Williams, S.C., Rogers, N.L., Marshall, N.S. et al. The effect of modafinil following acute CPAP withdrawal: a preliminary study. Sleep Breath 12, 359–364 (2008). https://doi.org/10.1007/s11325-008-0175-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11325-008-0175-9